LTI-03
Asset
Caveolin-1-derived peptide intended to protect alveolar epithelial cells, restore their function, and limit lung fibrosis.
- Stage
- Phase 2
- Modality
- Peptide
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Idiopathic pulmonary fibrosis
Phase 2, Recruiting, NCT06968845, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Owner and partners1
- Trials1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.